Literature DB >> 15804967

Pathophysiology of human paralytic rabies.

Thiravat Hemachudha1, Supaporn Wacharapluesadee, Erawady Mitrabhakdi, Henry Wilde, Kinjiro Morimoto, Richard A Lewis.   

Abstract

Furious rabies is a well-recognized clinical disorder in humans but the paralytic form is not as easily identified. The mechanisms responsible for the weakness and longer survival periods are not clear. Several hypotheses have been proposed, including rabies virus variants associated with a particular vector, location of wounds, incubation period, influence of prior rabies vaccination, and virus localization in the central nervous system (CNS). However, none of these have been substantiated. Regarding molecular analyses of rabies viruses isolated from both furious and paralytic rabies patients, only minor genetic variations with no specific patterns in glyco- (G), phospho- (P), and nucleoprotein (N) sequences have been identified and arginine 333 in G protein was present in all samples. Regional distribution of rabies virus antigenin rabies patients whose survival periods were 7 days or less and magnetic resonance imaging (MRI) of the CNS indicated brainstem and spinal cord as predilection sites regardless of clinical presentations. There are clinical, electrophysiological, and pathological indications that peripheral nerve dysfunction is responsible for weakness in paralytic rabies whereas in furious rabies, even in the absence of clinical weakness, abundant denervation potentials with normal sensory nerve conduction studies and proximal motor latencies suggest anterior horn cell dysfunction. The lack of cellular immunity to rabies virus antigen accompanied by an absence of cerebrospinal fluid (CSF) rabies neutralizing antibody in most paralytic rabies patients may argue against role of an immune response against rabies virus-positive axons. Aberrant immune responses to peripheral nerve antigen, in particular those mediated by one or more cellular-dependent mechanisms, may be involved as is supported by the absence of putative anti-ganglioside antibodies commonly found in immune-mediated peripheral nerve diseases. Longer survival period in paralytic rabies may possibly be related to currently unidentified mechanism(s) on neuronal gene expression, required for virus transcription/replication and for maintaining neuronal survival.

Entities:  

Mesh:

Year:  2005        PMID: 15804967     DOI: 10.1080/13550280590900409

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  58 in total

1.  A poliomyelitis-like syndrome from West Nile virus infection.

Authors:  A Arturo Leis; Dobrivoje S Stokic; Jo Lynn Polk; Victor Dostrow; Michael Winkelmann
Journal:  N Engl J Med       Date:  2002-09-23       Impact factor: 91.245

2.  Role of host immune response in the development of either encephalitic or paralytic disease after experimental rabies infection in mice.

Authors:  Y Iwasaki; W Gerhard; H F Clark
Journal:  Infect Immun       Date:  1977-10       Impact factor: 3.441

3.  Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery.

Authors:  N D Mazarakis; M Azzouz; J B Rohll; F M Ellard; F J Wilkes; A L Olsen; E E Carter; R D Barber; D F Baban; S M Kingsman; A J Kingsman; K O'Malley; K A Mitrophanous
Journal:  Hum Mol Genet       Date:  2001-09-15       Impact factor: 6.150

4.  The antigen-specific cell-mediated immune response in mice is suppressed by infection with pathogenic lyssaviruses.

Authors:  P Perrin; M Tino de Franco; C Jallet; F Fouque; S Morgeaux; N Tordo; J H Colle
Journal:  Res Virol       Date:  1996 Sep-Oct

5.  Rabies virus neuritic paralysis: immunopathogenesis of nonfatal paralytic rabies.

Authors:  F Weiland; J H Cox; S Meyer; E Dahme; M J Reddehase
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

6.  Extensive immune-mediated hippocampal damage in mice surviving infection with neuroadapted Sindbis virus.

Authors:  Takashi Kimura; Diane E Griffin
Journal:  Virology       Date:  2003-06-20       Impact factor: 3.616

Review 7.  Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges.

Authors:  Thiravat Hemachudha; Jiraporn Laothamatas; Charles E Rupprecht
Journal:  Lancet Neurol       Date:  2002-06       Impact factor: 44.182

8.  Pathogenicity of different rabies virus variants inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures.

Authors:  K Morimoto; D C Hooper; S Spitsin; H Koprowski; B Dietzschold
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  Paralysis of street rabies virus-infected mice is dependent on T lymphocytes.

Authors:  M Sugamata; M Miyazawa; S Mori; G J Spangrude; L C Ewalt; D L Lodmell
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

10.  Clinical spectrum of muscle weakness in human West Nile virus infection.

Authors:  A Arturo Leis; Dobrivoje S Stokic; Risa M Webb; Sally A Slavinski; Jonathan Fratkin
Journal:  Muscle Nerve       Date:  2003-09       Impact factor: 3.217

View more
  27 in total

1.  A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.

Authors:  Jingchen Ma; Hongchang Wang; Jun Li; Likuan Chang; Yun Xie; Zhonglin Liu; Yuliang Zhao; Claudius Malerczyk; Malerczyk Claudius
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.

Authors:  RongCheng Li; YanPing Li; ShuQing Wen; HuiChun Wen; Yi Nong; Zhaojun Mo; Fang Xie; Michele Pellegrini
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen).

Authors:  B J Mahendra; Dh Ashwath Narayana; Sharad Agarkhedkar; H S Ravish; B R Harish; Shalaka Agarkhedkar; S N Madhusudana; Ashwin Belludi; Khaleel Ahmed; Rekha Jonnalagedda; Hoshang Vakil; Chiranjiwi Bhusal; Ashwani Kumar Arora
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  NEUROLOGICAL INFECTIONS IN THE RETURNING INTERNATIONAL TRAVELER.

Authors:  May H Han; Melanie Walker; Joseph R Zunt
Journal:  Continuum (Minneap Minn)       Date:  2006-04

Review 5.  Perspectives in Diagnosis and Treatment of Rabies Viral Encephalitis: Insights from Pathogenesis.

Authors:  Anita Mahadevan; M S Suja; Reeta S Mani; Susarala K Shankar
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

6.  Injection of the sciatic nerve with TMEV: a new model for peripheral nerve demyelination.

Authors:  Kristen M Drescher; Steven M Tracy
Journal:  Virology       Date:  2006-10-09       Impact factor: 3.616

Review 7.  Rabies.

Authors:  Thiravat Hemachudha; Supaporn Wacharapluesadee; Jiraporn Laothamatas; Henry Wilde
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

8.  Rabies virus is recognized by the NLRP3 inflammasome and activates interleukin-1β release in murine dendritic cells.

Authors:  Tessa M Lawrence; Andrew W Hudacek; Marcel R de Zoete; Richard A Flavell; Matthias J Schnell
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

Review 9.  The cell biology of rabies virus: using stealth to reach the brain.

Authors:  Matthias J Schnell; James P McGettigan; Christoph Wirblich; Amy Papaneri
Journal:  Nat Rev Microbiol       Date:  2010-01       Impact factor: 60.633

10.  Furious and paralytic rabies of canine origin: neuroimaging with virological and cytokine studies.

Authors:  Jiraporn Laothamatas; Supaporn Wacharapluesadee; Boonlert Lumlertdacha; Sumate Ampawong; Vera Tepsumethanon; Shanop Shuangshoti; Patta Phumesin; Sawwanee Asavaphatiboon; Ladawan Worapruekjaru; Yingyos Avihingsanon; Nipan Israsena; Monique Lafon; Henry Wilde; Thiravat Hemachudha
Journal:  J Neurovirol       Date:  2008-04       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.